This article is more than 5 years old. Information may no longer be current.

Nemus, Nanomerics to develop ocular formulation for glaucoma treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Nemus Bioscience and Nanomerics have signed a development agreement to develop a topical ocular formulation of tetrahydracannabinol-valine-hemisuccinate, according to a Nemus press release.

The active component of NB1111, a product candidate from Nemus for the treatment of glaucoma, is tetrahydracannabinol-valine-hemisuccinate (THCVHS), the prodrug of THC, the release said. The agreement involves initial studies assessing the preparation of clinical-grade eye drops using Nanomerics’ patented Molecular Envelope Technology (MET).

“Historically, it has been challenging to formulate hydrophobic, or fat-soluble, cannabinoid molecules for efficient and predictable entry into the body, especially the eye,” Brian Murphy, MD, MBA, Nemus CEO and chief medical officer, said in the release. “Nemus has found the MET technology profile to be supportive of the work performed to-date using the more hydrophilic THCVHS, which was designed to cross physiologic barriers more efficiently. Developing this formulation is an important step before conducting human studies.”

Nemus plans to address multiple types of eye disease with a diverse cannabinoid-based ocular platform, Murphy added.